Skip to main content
. 2019 Sep 16;37(34):3183–3191. doi: 10.1200/JCO.19.00917

FIG 2.

FIG 2.

Kaplan-Meier curves for time with toxicity (TOX), mean progression-free survival (PFS) generalized gamma distributions, and mean time without symptoms or toxicity (TWiST) for (A) niraparib and (B) routine surveillance (RS) in the gBRCAmut cohort and for (C) niraparib and (D) RS in the non-gBRCAmut cohort over a 20-year time horizon. gBRCAmut, germline BRCA mutation.